Nearly half of hypertensive patients struggle to achieve target blood pressure levels despite multiple available medications, creating a persistent gap that contributes to cardiovascular mortality worldwide. The challenge extends beyond drug effectiveness to include daily adherence burdens and complex treatment regimens that undermine real-world outcomes. Zilebesiran represents a paradigm shift by targeting the genetic blueprint of blood pressure regulation itself. This RNA interference therapeutic silences hepatic angiotensinogen production at the cellular level, achieving sustained reductions in circulating angiotensin II—the master hormone driving blood pressure elevation. Clinical trials demonstrate remarkable potency, with single subcutaneous injections reducing 24-hour systolic blood pressure by 10-27 mmHg while suppressing angiotensinogen levels by over 90%. The therapeutic window extends up to six months per dose, delivered through a GalNAc-conjugated siRNA that specifically targets liver cells via asialoglycoprotein receptors. This precision approach represents a fundamental departure from traditional daily medications that block downstream RAAS components. From a longevity perspective, this technology addresses one of the most significant modifiable risk factors for cardiovascular disease through a mechanism that could dramatically improve treatment adherence. The KARDIA trials suggest zilebesiran functions effectively both as monotherapy and alongside conventional antihypertensives without major renal complications. However, long-term safety data remain limited, and the irreversible nature of genetic silencing requires careful consideration. If validated in larger populations, this approach could transform hypertension management from a daily pharmaceutical burden into periodic preventive interventions.